Dr Peter McCullough: CDC Promotes JYNNEOS "MAX your VAX" Mpox Vaccination
A recent pharmaceutical “MAX your VAX” advertisement from the CDC caught my attention for several reasons:
Here is what the fully FDA approved JYNNEOS vaccine package insert says about heart damage and a > 6x increased risks of cardiac adverse events.
The White House, Senate, and Congress should be asking why is the CDC promoting the JYNNEOS vaccine now? How are they allowed to violate pharmaceutical advertising laws?
For these and many reasons, bio-pharmaceutical advertising by government agencies should be abolished. Investigations into the driving forces behind CDC advertising on behalf of vaccine companies should be investigated. Individuals and agencies should be brought to justice.
References:
- the CDC is not a drug company and should not be promoting products from Bavarian Nordic,
- the national and public health emergencies have expired for Monkeypox on January 31, 2023,
- the JYNNEOS vaccine has well-recognized risks for heart damage (troponin elevation) and cardiac adverse events of special interest especially in those previously vaccinated against smallpox,
- the peak age and gender group is men in their twenties and thirties—the same demographic shown in the internet promotion—highest risk for vaccine heart damage.
Here is what the fully FDA approved JYNNEOS vaccine package insert says about heart damage and a > 6x increased risks of cardiac adverse events.
The White House, Senate, and Congress should be asking why is the CDC promoting the JYNNEOS vaccine now? How are they allowed to violate pharmaceutical advertising laws?
For these and many reasons, bio-pharmaceutical advertising by government agencies should be abolished. Investigations into the driving forces behind CDC advertising on behalf of vaccine companies should be investigated. Individuals and agencies should be brought to justice.
References:
- JYNNEOS is a vaccine indicated for prevention of smallpox and monkeypox disease in adults.
- Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial.
Comments
Post a Comment